Sionna Therapeutics, Inc. (SION): who owns it and who trades it
As of Nov 16, 2026, SION insiders reported 62 open-market sales worth $95.4M and no purchases in the last 12 months, with 60% of the sale value made under pre-set 10b5-1 plans. The largest seller was Peter A. Thompson (Director), with $49.3M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Sionna Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SION
147 funds and institutions reported SION shares worth $2.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 21.9%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 9.91M | 21.94% | $436M | No change |
| Tpg Gp A, LLC | 6.49M | 14.39% | $286M | No change |
| Viking Global Investors LP | 3.20M | 7.08% | $141M | No change |
| Atlas Venture Life Science Advisors, LLC | 3.00M | 6.63% | $132M | No change |
| Orbimed Advisors LLC | 2.56M | 5.66% | $112M | -28% |
| Enavate Sciences Gp, LLC | 2.48M | 5.49% | $109M | No change |
| Adage Capital Partners Gp, L.l.c. | 1.60M | 3.54% | $70.4M | +967% |
| JPMorgan Chase & Co | 1.49M | 3.30% | $64.1M | – |
| BlackRock, Inc. | 1.47M | 3.27% | $64.9M | +14% |
| Jennison Associates LLC | 1.17M | 2.60% | $51.6M | -19% |
| Citadel Advisors LLC | 1.15M | 2.54% | $50.5M | -2% |
| Vanguard Capital Management LLC | 1.13M | 2.51% | $49.8M | +10% |
| State Street Corp | 1.02M | 2.26% | $44.9M | +35% |
| Perceptive Advisors LLC | 905,000 | 2.00% | $39.8M | +37% |
| Deerfield Management Company, L.P. | 680,916 | 1.51% | $30M | -30% |
| California State Teachers Retirement System | 653,339 | 1.45% | $14.9M | +75169% |
| Siren, L.L.C. | 610,515 | 1.35% | $26.9M | +104% |
| T. Rowe Price Associates | 478,016 | 1.06% | $21M | -37% |
| Eventide Asset Management, LLC | 474,981 | 1.05% | $20.9M | -26% |
| Geode Capital Management, LLC | 457,145 | 1.01% | $20.1M | +17% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, SION insiders reported $0 of open-market purchases and $95.4M of sales. 60% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Ra Capital Management, L.P. +5 | Director | Sale | 3.42M | $6.32 | $21.6M | Form 4 |
| Sep 17, 2026 | Ra Capital Management, L.P. +5 | Director | Sale | 33,800 | $7.46 | $252K | Form 4 |
| Jul 7, 2026 | Peter A. Thompson | Director | Sale plan | 85,918 | $44.86 | $3.9M | Form 4 |
| Jul 6, 2026 | Jennifer Fitzpatrick | Chief Legal Officer | Sale plan | 10,250 | $43.60 | $447K | Form 4 |
| Jun 30, 2026 | Peter A. Thompson | Director | Sale plan | 115,844 | $45.50 | $5.3M | Form 4 |
| May 27, 2026 | Peter A. Thompson | Director | Sale plan | 101 | $44.49 | $4.5K | Form 4 |
| May 11, 2026 | Peter A. Thompson | Director | Sale plan | 184,639 | $46.22 | $8.5M | Form 4 |
| May 8, 2026 | Peter A. Thompson | Director | Sale plan | 59,767 | $44.58 | $2.7M | Form 4 |
| May 7, 2026 | Peter A. Thompson | Director | Sale plan | 48,546 | $44.61 | $2.2M | Form 4 |
| Apr 18, 2026 | Peter A. Thompson | Director | Sale plan | 2,948 | $44.52 | $131K | Form 4 |
| Apr 17, 2026 | Peter A. Thompson | Director | Sale plan | 52,397 | $44.68 | $2.3M | Form 4 |
| Apr 16, 2026 | Peter A. Thompson | Director | Sale plan | 226,906 | $45.34 | $10.3M | Form 4 |
| Apr 15, 2026 | Peter A. Thompson | Director | Sale plan | 235,863 | $44.64 | $10.5M | Form 4 |
| Apr 14, 2026 | Peter A. Thompson | Director | Sale plan | 47,814 | $44.51 | $2.1M | Form 4 |
| Mar 5, 2026 | Jennifer Fitzpatrick | Chief Legal Officer | Sale plan | 10,250 | $33.86 | $347K | Form 4 |
| Feb 3, 2026 | Peter A. Thompson | Director | Sale plan | 29,063 | $44.58 | $1.3M | Form 4 |
| Feb 2, 2026 | Peter A. Thompson | Director | Sale plan | 1,890 | $44.57 | $84.2K | Form 4 |
| Jan 22, 2026 | Jon Winkelried +2 | 10% owner | Sale | 250,000 | $40.00 | $10M | Form 4 |
| Dec 24, 2025 | OrbiMed Capital GP VIII LLC +1 | Director | Sale plan | 33,356 | $44.55 | $1.5M | Form 4 |
| Dec 19, 2025 | OrbiMed Capital GP VIII LLC +1 | Director | Sale plan | 875 | $44.49 | $38.9K | Form 4 |
| Dec 18, 2025 | OrbiMed Capital GP VIII LLC +1 | Director | Sale plan | 100 | $44.49 | $4.4K | Form 4 |
| Dec 17, 2025 | OrbiMed Capital GP VIII LLC +1 | Director | Sale plan | 900 | $44.50 | $40K | Form 4 |
| Dec 5, 2025 | Jennifer Fitzpatrick | Chief Legal Officer | Sale plan | 10,250 | $40.52 | $415K | Form 4 |
| Nov 26, 2025 | Orbimed Advisors Llc +1 | Director | Sale plan | 1,600 | $44.49 | $71.2K | Form 4 |
| Nov 25, 2025 | Orbimed Advisors Llc +1 | Director | Sale plan | 11,890 | $44.60 | $530K | Form 4 |
| Nov 24, 2025 | Orbimed Advisors Llc +1 | Director | Sale plan | 94,583 | $44.54 | $4.2M | Form 4 |
| Nov 21, 2025 | Peter Kolchinsky +5 | Director | Sale | 7,609 | $39.50 | $301K | Form 4 |
| Nov 21, 2025 | Peter Kolchinsky +5 | Director | Sale | 1,210 | $39.50 | $47.8K | Form 4 |
| Nov 21, 2025 | Peter Kolchinsky +5 | Director | Sale | 9,924 | $39.50 | $392K | Form 4 |
| Nov 21, 2025 | Peter Kolchinsky +5 | Director | Sale | 6,440 | $39.50 | $254K | Form 4 |
| Nov 20, 2025 | Peter Kolchinsky +5 | Director | Sale | 150 | $39.89 | $6K | Form 4 |
| Nov 20, 2025 | Peter Kolchinsky +5 | Director | Sale | 1,235 | $39.89 | $49.3K | Form 4 |
| Nov 20, 2025 | Peter Kolchinsky +5 | Director | Sale | 801 | $39.89 | $32K | Form 4 |
| Nov 20, 2025 | Peter Kolchinsky +5 | Director | Sale | 947 | $39.89 | $37.8K | Form 4 |
| Nov 20, 2025 | Peter Kolchinsky +5 | Director | Sale | 96 | $40.50 | $3.9K | Form 4 |
| Nov 20, 2025 | Peter Kolchinsky +5 | Director | Sale | 512 | $40.50 | $20.7K | Form 4 |
| Nov 20, 2025 | Peter Kolchinsky +5 | Director | Sale | 604 | $40.50 | $24.5K | Form 4 |
| Nov 20, 2025 | Peter Kolchinsky +5 | Director | Sale | 788 | $40.50 | $31.9K | Form 4 |
| Nov 19, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 9 | $40.61 | $365 | Form 4 |
| Nov 19, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 8 | $40.61 | $325 | Form 4 |
| Nov 19, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 12 | $40.61 | $487 | Form 4 |
| Nov 19, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 2 | $40.61 | $81 | Form 4 |
| Nov 19, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 14,325 | $40.01 | $573K | Form 4 |
| Nov 19, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 12,126 | $40.01 | $485K | Form 4 |
| Nov 19, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 18,684 | $40.01 | $748K | Form 4 |
| Nov 19, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 2,276 | $40.01 | $91.1K | Form 4 |
| Nov 18, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 1,770 | $39.57 | $70K | Form 4 |
| Nov 18, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 2,728 | $39.57 | $108K | Form 4 |
| Nov 18, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 332 | $39.57 | $13.1K | Form 4 |
| Nov 18, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 2,092 | $39.57 | $82.8K | Form 4 |
| Nov 17, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 53 | $42.10 | $2.2K | Form 4 |
| Nov 17, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 433 | $42.10 | $18.2K | Form 4 |
| Nov 17, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 280 | $42.10 | $11.8K | Form 4 |
| Nov 17, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 331 | $42.10 | $13.9K | Form 4 |
| Nov 17, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 10,707 | $41.05 | $440K | Form 4 |
| Nov 17, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 9,063 | $41.05 | $372K | Form 4 |
| Nov 17, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 13,964 | $41.05 | $573K | Form 4 |
| Nov 17, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 1,701 | $41.05 | $69.8K | Form 4 |
| Nov 17, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 13,734 | $40.20 | $552K | Form 4 |
| Nov 17, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 11,626 | $40.20 | $467K | Form 4 |
| Nov 17, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 17,913 | $40.20 | $720K | Form 4 |
| Nov 17, 2025 | Ra Capital Management, L.P. +5 | Director | Sale | 2,182 | $40.20 | $87.7K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Peter A. Thompson | Director | – | $49.3M | Jul 7, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | – | $27.3M | Sep 17, 2026 |
| Jon Winkelried | 10% owner | – | $10M | Jan 22, 2026 |
| Orbimed Advisors Llc | Director | – | $4.8M | Nov 26, 2025 |
| OrbiMed Capital GP VIII LLC | Director | – | $1.6M | Dec 24, 2025 |
| Jennifer Fitzpatrick | Chief Legal Officer | – | $1.2M | Jul 6, 2026 |
| Peter Kolchinsky | Director, 10% owner | – | $1.2M | Nov 21, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SION short interest
Moderate short interest. 9.3% of SION shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 11%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.21M SION shares were sold short, 9.3% of the shares outstanding, up 14.6% from the report before. At the average daily volume of 1.03M shares, buying them all back would take about 4.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.21M | 9.31% | +15% | 1.03M | 4.1 |
| Oct 15, 2026 | 3.68M | 8.13% | -3% | 983,094 | 3.7 |
| Sep 30, 2026 | 3.80M | 8.40% | -4% | 1.65M | 2.3 |
| Sep 15, 2026 | 3.97M | 8.77% | -8% | 1.28M | 3.1 |
| Aug 31, 2026 | 4.30M | 9.51% | +1% | 1.64M | 2.6 |
| Aug 14, 2026 | 4.25M | 9.40% | +1% | 7.35M | 1.0 |
| Jul 31, 2026 | 4.20M | 9.29% | -20% | 618,000 | 6.8 |
| Jul 15, 2026 | 5.26M | 11.64% | -5% | 456,753 | 11.5 |
| Jun 30, 2026 | 5.52M | 12.23% | +11% | 544,387 | 10.1 |
| Jun 15, 2026 | 5.00M | 11.07% | +8% | 360,220 | 13.9 |
| May 29, 2026 | 4.64M | 10.27% | -2% | 319,204 | 14.5 |
| May 15, 2026 | 4.74M | 10.50% | +12% | 421,449 | 11.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Sionna Therapeutics company events
Sionna Therapeutics filed 7 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Sep 14, 2026LeadershipDeparture of Chief Business Officer; Officer Roles In connection with the Restructuring, the employment of Caroline Stark Beer, M.B.A., the Company’s Chief Business Officer, was terminated without cause, effective as of September 15, 2026. Filing
- Aug 10, 2026AnnouncementSionna Therapeutics, Inc., or the Company, announced topline data from both its PreciSION CF Phase 2a proof-of-concept trial of SION-719 when added to current standard of care and its Phase 1 trial of SION-451-based proprietary dual combinations in healthy subjects. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Mar 2, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Sionna Therapeutics financials
Famous investors that hold SION
4 of the 50 well-known investors we track reported holding SION in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $16.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 3.20M | $16.8M | 0.1% | No change |
| Israel Englander · Millennium Management | Q3 2026 | 1.46M | $7.7M | 0.0% | +429% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 263,401 | $1.4M | 0.0% | +434% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 16,188 | $85.1K | 0.0% | -99% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SION in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 9, 2026 | THE GOLDMAN SACHS GROUP, INC. | 13G | 5.8% |
| Nov 9, 2026 | THE GOLDMAN SACHS GROUP, INC. | 13G | 5.8% |
Questions about Sionna Therapeutics, Inc. (SION) stock
Who owns the most SION stock?
The largest reported owner of Sionna Therapeutics, Inc. (SION) is Ra Capital Management, L.P., with 21.9% of the company. In total, 147 funds and institutions reported holding SION at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are SION insiders buying or selling?
In the last 12 months, SION insiders reported no open-market purchases and 62 sales worth $95.4M. The latest trade was on Sep 17, 2026. See every trade.
What is the short interest in SION?
As of Oct 30, 2026, 4.21M SION shares were sold short, 9.3% of the shares outstanding, up 14.6% from the report before. At the average daily volume of 1.03M shares, buying them all back would take about 4.1 trading days (days to cover). See the history.
Which famous investors hold SION?
4 of the 50 well-known investors we track reported SION in their latest 13F filing, including Andreas Halvorsen, Israel Englander, Steve Cohen. The largest position is worth $16.8M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.